Skip to main content
AAN.com

Abstract

The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them. REM sleep behavior disorder, severe neuroleptic sensitivity, and reduced striatal dopamine transporter activity on functional neuroimaging are given greater diagnostic weighting as features suggestive of a DLB diagnosis. The 1-year rule distinguishing between DLB and Parkinson disease with dementia may be difficult to apply in clinical settings and in such cases the term most appropriate to each individual patient should be used. Generic terms such as Lewy body (LB) disease are often helpful. The authors propose a new scheme for the pathologic assessment of LBs and Lewy neurites (LN) using alpha-synuclein immunohistochemistry and semiquantitative grading of lesion density, with the pattern of regional involvement being more important than total LB count. The new criteria take into account both Lewy-related and Alzheimer disease (AD)-type pathology to allocate a probability that these are associated with the clinical DLB syndrome. Finally, the authors suggest patient management guidelines including the need for accurate diagnosis, a target symptom approach, and use of appropriate outcome measures. There is limited evidence about specific interventions but available data suggest only a partial response of motor symptoms to levodopa: severe sensitivity to typical and atypical antipsychotics in ∼50%, and improvements in attention, visual hallucinations, and sleep disorders with cholinesterase inhibitors.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (6.5_04_1_lewy_body_dementia_-_review_szermer.doc)
File (6.5_04_2_lewy_body_dementia_-_komentarz_barcikowska.doc)
File (e1.doc)

References

1.
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124.
2.
McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop. Neurology 1999;53:902–905.
3.
McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19–28.
4.
Litvan I, Bhatia KP, Burn DJ, et al. SIC Task Force Appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003;18:467–486.
5.
Luis CA, Barker WW, Gajaraj K, et al. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry 1999;14:526–533.
6.
Mega MS, Masterman DL, Benson F, et al. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology 1996;47:1403–1409.
7.
Del Ser T, Hachinski V, Merskey H, Munoz DG. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord 2001;15:31–44.
8.
Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003;60:1586–1590.
9.
Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry 2004;161:843–849.
10.
McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992;22:911–922.
11.
Collerton D, Burn D, McKeith I, O'Brien J. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord 2003;16:229–237.
12.
Calderon J, Perry RJ, Erzinclioglu SW, Berrios GE, Dening TR, Hodges JR. Perception, attention, and working memory are dispropor-tionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:157–164.
13.
Walker Z, Allan RL, Shergill S, Katona CLE. Neuropsychological performance in Lewy body dementia and Alzheimer's disease. Br J Psychiatry 1997;170:156–158.
14.
Connor DJ, Salmon DP, Sandy TJ, Galasko D, Hansen LA, Thal LJ. Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Arch Neurol 1998;55:994–1000.
15.
Mormont E, Grymonprez LL, Baisset-Mouly C, Pasquier F. The profile of memory disturbance in early Lewy body dementia differs from that in Alzheimer's disease. Rev Neurol. 2003; 159: 762–766.
16.
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387–392.
17.
Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229–237.
18.
Molloy S, McKeith I, O'Brien JT, Burn D. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005 76:1200–1203.
19.
Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004;63:376–378.
20.
Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1215–1220.
21.
Ballard CG, Aarsland D, McKeith IG, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002;59:1714–1720.
22.
Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001;16:528–536.
23.
Boeve BF, Silber MH, Ferman TJ, et al. REM sleep behaviour disorder and degenerative dementia. An association likely reflecting Lewy body disease. Neurology 1998;51:363–370.
24.
Wenning GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 1999;67:620–623.
25.
Aarsland D, Ballard C, McKeith I, Perry RH, Larsen JP. Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:374–379.
26.
Aarsland D, Ballard C, Larsen JP, McKeith I, O'Brien J, Perry R. Marked neuroleptic sensitivity in dementia with Lewy bodies and Parkinson's disease. J Clin Psychiatry 2005;66:633–637.
27.
McKeith I, Del-Ser T, Spano PF, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–2036.
28.
Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509–2518.
29.
Apaydin H, Ahlskog E, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology. Later-developing dementia and loss of levodopa response. Arch Neurol 2002;59:102–112.
30.
Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916–1921.
31.
Kovari E, Gold G, Giannakopoulos P, Lovero P, Surini M, Bouras C. Lewy body pathology in different neurodegenerative diseases. Brain Pathol 2000;10:518–519.
32.
Cummings JL. Fluctuations in cognitive function in dementia with Lewy bodies. Lancet Neurol 2004;3:266–387.
33.
Bradshaw JSM, Hopwood M, Anderson V, Brodtmann A. Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg Psychiatry 2004;75:382–387.
34.
Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate from AD and normal aging. Neurology 2004;62:181–187.
35.
Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252–256.
36.
Walker MP, Ayre GA, Cummings JL, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease and vascular dementia. Neurology 2000;54:1616–1624.
37.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.
38.
Mosimann UP, Rowan EN, Partington CE, et al. Characteristics of visual hallucinations in Parkinson's disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry (in press).
39.
Mori E, Shimomura T, Fujimori M, et al. Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol 2000;57:489–493.
40.
Mosimann UP, Mather G, Wesnes K, O'Brien J, Burn D, McKeith IG. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004;63:2091–2096.
41.
Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391–403.
42.
Lobotesis K, Fenwick JD, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643–649.
43.
Colloby SJ, Fenwick JD, Williams ED, et al. A comparison of 99mTc-HMPAO SPECT changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. Eur J Nucl Med 2002;29:615–622.
44.
Higuchi M, Tashiro M, Arai H, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000;162:247–256.
45.
Perry EK, McKeith I, Thompson P, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease and Alzheimer's disease. Ann NY Acad Sci 1991;640:197–202.
46.
Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868–876.
47.
McKeith IG, Wesnes KA, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004;18:94–100.
48.
Ballard C, O'Brien J, Swann A, et al. One year follow-up of parkinsonism in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2000;11:219–222.
49.
Burn DJ, Rowan EN, Minett T, et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 2003;18:884–889.
50.
Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease. New York: McMillan, 1987;153–163.
51.
Ballard C, McKeith I, Burn D, et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 1997;96:366–371.
52.
Duda JE, Giasson BI, Mabon ME, Lee VMY, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002;52:205–210.
53.
Boeve BF, Silber MH, Ferman TJ. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:146–157.
54.
Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003;61:40–45.
55.
McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673–678.
56.
Swanberg MM, Cummings JL. Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug Safety 2002;25:511–523.
57.
Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415–1423.
58.
Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122:1449–1468.
59.
O'Brien JT, Colloby SJ, Fenwick J, et al. Dopamine transporter loss visualised with FP-CIT SPECT in dementia with Lewy bodies. Arch Neurol 2004;61:919–925.
60.
Walker Z, Costa DC, Walker RWH, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134–140.
61.
Horimoto Y, Matsumoto M, Akatsu H, et al. Autonomic dysfunctions in dementia with Lewy bodies. J Neurol 2003;250:530–533.
62.
Kuzuhara S, Yoshimura M. Clinical and neuropathological aspects of diffuse Lewy body disease in the elderly. Adv Neurol 1993;60:464–469.
63.
Del-Ser T, Munoz DG, Hachinski V. Temporal pattern of cognitive decline and incontinence is different in Alzheimer's disease and diffuse Lewy body disease. Neurology 1996;46:682–686.
64.
Ballard C, Shaw F, McKeith I, Kenny RA. High prevalence of neurovascular instability in neurodegenerative dementias. Neurology 1998;51:1760–1762.
65.
Birkett DP, Desouky A, Han L, Kaufman M. Lewy bodies in psychiatric patients. Int J Geriatr Psychiatry 1992;7:235–240.
66.
Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord. 2003; 18(suppl 6): S2–12.
67.
McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of Consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050–1058.
68.
Galasko D. Biomarkers in non-Alzheimer dementias. Clin Neurosci Res 2004;3:375–381.
69.
Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT. MRI volumetric study of dementia with Lewy bodies. A comparison with AD and vascular dementia. Neurology 2000;54:1304–1309.
70.
Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999;52:1153–1158.
71.
Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O'Brien JT. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. Neurology 2003;61:1191–1195.
72.
Ishii K, Hosaka K, Mori T, Mori E. Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med 2004;18:447–451.
73.
Albin RL, Minoshima S, Damato CJ, Frey KA, Kuhl DA, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462–466.
74.
Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358–365.
75.
Middelkoop HAM, van der Flier WM, Burton EJ, et al. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology 2001;57:2117–2120.
76.
Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000;15:911–916.
77.
O'Brien JT, Paling S, Barber R, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001;56:1386–1388.
78.
Yoshita M, Taki J, Yamada M. A clinical role for I-123 MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2001;71:583–588.
79.
Taki J, Yoshita M, Yamada M, Tonami N. Significance of I-123-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: It can be a specific marker for Lewy body disease. Ann Nucl Med 2004;18:453–461.
80.
Kosaka K. Lewy bodies in cerebral cortex. Report of three cases. Acta Neuropathol 1978;42:127–134.
81.
Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree—A new disease? Clin Neuropathol 1984;3:185–192.
82.
Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000;10:378–384.
83.
McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2002;16:2136–2148.
84.
Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004;279:4625–4631.
85.
Lippa CF, McKeith I. Dementia with Lewy bodies: improving diagnostic criteria. Neurology 2003;60:1571–1572.
86.
Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) II. Standardisation of the neuropathological assessment of Alzheimer's disease. Neurology 1991;41:479–486.
87.
NIA. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18(4 suppl):s1–2.
88.
Lopez OL, Becher JT, Kaufer DI, et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol 2002;59:43–46.
89.
Harding AJ, Kril JJ, Halliday GM. Practical measures to simplify the Braak tangle staging method for routine pathological screening. Acta Neuropathol 2000;99:199–208.
90.
Braak H, Del Tredici K, Rub U, de Vos RAI, Steur E, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197–211.
91.
Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153:1365–1370.
92.
Popescu A, Lippa CF, Lee VMY, Trojanowski JQ. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 2004;61:1915–1919.
93.
Tsuang DW, DiGiacomo L, Bird TD. Familial occurrence of dementia with Lewy bodies. Am J Geriatr Psychiatry 2004;12:179–188.
94.
Gwinn-Hardy K, Singleton AA. Familial Lewy body diseases. J Geriatr Psychiatry Neurol 2002;15:217–223.
95.
Trembath Y, Rosenberg C, Ervin JF, et al. Lewy body pathology is a frequent co-pathology in familial Alzheimer's disease. Acta Neuropathol 2003;105:484–488.
96.
Singleton A, Gwinn-Hardy K. Parkinson's disease and dementia with Lewy bodies: a difference in dose? Lancet 2004;364:1105–1107.
97.
Johnson J, Hague SM, Hanson M, et al. SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. Neurology 2004;63:554–556.
98.
Barber R, Panikkar A, McKeith IG. Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry 2001;16:S12–S18.
99.
Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of dementia with Lewy bodies. Exp Opin Pharmacother 2003;4:2027–2037.
100.
Terao T, Shimomura T, Izumi Y, Nakamura J. Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies. J Clin Psychiatry 2003;64:1520–1521.
101.
Burke WJ, Pfeiffer RF, McComb RD. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998;10:227–229.
102.
Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment. Mov Disord 2001;16:1171–1174.
103.
Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:164–171.
104.
Samuel W, Caligiuri M, Galasko D, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000;15:794–802.
105.
Grace J, Daniel S, Stevens T, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial. Int Psychogeriatr 2001; 13: 199–205.
Letters to the Editor
22 December 2005
Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium
Laura Bonanni, Dept. of Oncology and Neuroscience, University Chieti-Pescara, Neurophysiopathology
Astrid Thomas, Marco Onofrj

In the last revision of criteria for the diagnosis of dementia with Lewy bodies (LBD) [1], temporal lobe transient slow waves (in the text) or sharp waves (in table 1) on EEG was reported as a supportive feature for the diagnosis of LBD.

The only quoted reference is a review [2] reporting that "standard EEG may show early slowing, epoch-by-epoch fluctuation, and transient temporal slow-wave activity." The first reference quoted in the review [3] described EEG recordings in 11 Alzheimer disease (AD) and in 14 LBD patients. All but two patients showed "abnormal EEG with alpha activity decreased outside the normal frequency." Preservation of alpha activity was more common in AD, 55% than in LBD, 36%, p=0.45. 55% AD and 79% LBD patients had delta components. Temporal lobe transients were seen more often in LBD patients (50%) than in AD patients (18%) (p=0.11).

The second reference [4] described normal EEG patterns in three AD patients and in no LBD patients, mild but excessive theta activity, bitemporal spikes, or both in one AD patient and in one LBD patient, moderate excessive theta activity diffusely or bursts of bisynchronous, diffuse rhythmic 2 to 3Hz waves in 14 AD and 13 LBD patients and one or more persistent diffuse delta, bisynchronous spikes or sharp waves, and triphasic waves in two AD and six LBD patients. There was no significant difference in the EEG patterns between the two groups.

The authors stated that EEG is not diagnostic of LBD, failing to differentiate it from AD. The third reference was a single case report. Only one Quantitative EEG study is quoted in the review [5], describing variability of mean frequencies in LBD, but only 15 LBD and 15 AD were studied: frequency variability was expressed as difference in standard deviations of the mean frequencies, making the real epoch-to-epoch variations unclear. This difference was 2.91 LBD, 2.42 AD, 2.06 controls, meaning that the frequency variability in controls was about 3Hz. This is not surprising if the variability represents intra-group differences, but is unacceptable if it represents variations in the single controls.

The only figure shows EEG map plots with variability in the 5-22Hz range, incongruent with descriptions of theta-delta activity. Therefore, literature on EEG recordings in LBD includes anecdotal reports or inconclusive findings. It could be more appropriate, for a consensus statement, to conclude that finding EEG abnormalities does not exclude the diagnosis of LBD, instead of asserting that EEG abnormalities support LBD diagnosis.

References

1. McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies. Third report of the LBD consortium. Neurology 2005 October 19, as doi:10.1212/01.wnl.0000187889.17253.b1.

2. McKeith I, Mintzer J, Aarlsand D, et al, Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19-28.

3. Briel RCG, McKeith IG, Barker WA, et al. EEG findings in dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999; 66: 401-403.

4. Barber PA, Varma AR, Lloyd JJ, Haworth B, Snowden JS, Neary D. The electroencephalogram in dementia with Lewy bodies. Acta Neurol Scand 2000; 101: 53-56.

5. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology 2000; 54:1616-1624.

The authors report no conflicts of interest.

22 December 2005
Reply from the Authors
Ian G. McKeith, University of Newcastle upon Tyne

We thank Bonanni et al for their interest in our article. Features listed as "supportive" of a clinical diagnosis of DLB in the revised clinical diagnostic criteria are defined in the text of the paper as being "commonly present in DLB but (which) lack sufficient diagnostic specificity to be categorised as core or suggestive". [1]

The evidence regarding EEG abnormalities in DLB is limited. Published reports, which were previously summarized, [2] suggest that the standard EEG is often abnormal with slowing into theta and delta ranges and with a tendency to temporal lobe abnormalities including slow wave transients, and bisynchronous spikes, sharp and triphasic waves. No single pattern is typical. Our inclusion of such features as supportive of a DLB diagnosis does not imply that their presence can reliably differentiate DLB from AD or any other dementia. We merely suggest that their presence is consistent with, i.e. supportive of, a clinical diagnosis of DLB.

Dr Bonanni's suggestion that we might better have worded our recommendation as "finding EEG abnormalities does not exclude the diagnosis of LBD" is a more conservative way of saying the same thing but one that would probably be of less benefit in helping clinicians to improve their detection of DLB.

More research is needed, although it seems unlikely that the standard EEG will play a major part in DLB diagnosis. Other investigative techniques including functional neuro-imaging and cardiac scintigraphy appear to have high potential.

The authors report no conflicts of interest.

Information & Authors

Information

Published In

Neurology®
Volume 65Number 12December 27, 2005
Pages: 1863-1872
PubMed: 16237129

Publication History

Published online: October 19, 2005
Published in print: December 27, 2005

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

I. G. McKeith, MD, FMedSci
T. Del Ser, MD, PhD
S. Gauthier, MD, FRCPC
E. Gomez-Tortosa, MD, PhD
R. N. Kalaria, FRCPath
V.M.Y. Lee, PhD, MBA
S. Minoshima, MD, PhD
E. B. Mukaetova-Ladinska, MD, PhD
F. Pasquier, MD, PhD
J. Q. Trojanowski, MD, PhD
for the Consortium on DLB
Author affiliations
From the Institute for Ageing and Health (Drs. McKeith, O'Brien, E.K. Perry, Burn, Kalaria, Kenny, Mukaetova-Ladinska, and R.H. Perry), University of Newcastle upon Tyne, UK; Department of Neuropathology (Dr. Dickson), Mayo Clinic Jacksonville, FL; Division of Pathology (Dr. Lowe), School of Molecular Medical Sciences, University of Nottingham, UK; Department of Neurology (Dr. Emre), Istanbul University, Istanbul Faculty of Medicine, Turkey; UBC Division of Neurology (Dr. Feldman), University of British Columbia, Vancouver, Canada; Department of Neurology (Dr. Cummings), UCLA Medical School Alzheimer's Disease Center, Los Angeles, CA; Parkinson's Disease Research, Education and Clinical Center (Dr. Duda), Philadelphia VAMC, PA; Memory Disorders Program (Dr. Lippa), Drexel University School of Medicine, Philadelphia, PA; Section of Geriatric Psychiatry (Dr. Aarsland), Stavanger University Hospital, Norway; Department of Geriatric & Respiratory Medicine (Dr. Arai), Tohoku University School of Medicine, Miyagi, Japan; Wolfson Centre for Age-Related Diseases (Dr. Ballard), London, UK; Department of Neurology (Dr. Boeve), Mayo Clinic, Rochester, MN; Institute of Nuclear Medicine (Dr. Costa), HPP Medicina Molecular, SA, Porto, Portugal; Section of Neurology (Dr. del Ser), Hospital Severo Ochoa, Madrid, Spain; Hopital La Salpêtrière (Dr. Dubois), Paris, France; Depts. of Neuroscience (Dr. Galasko) and Pathology (Dr. Hansen), University of California San Diego, La Jolla; MCSA Alzheimer's Disease Research Unit (Dr. Gauthier), McGill Centre for Studies in Aging, Quebec, Canada; Department of Neurological Sciences (Dr. Goetz), Rush University Medical Center, Chicago, IL; Fundación Jiménez Diaz (Dr. Gómez-Tortosa), Servicio de Neurología, Madrid, Spain; Prince of Wales Medical Research Institute (Dr. Halliday), Sydney, Australia; Laboratory of Neurogenetics (Dr. Hardy), National Institute on Aging, Bethesda, MD; Department of Neuropathology & Neuroscience (Dr. Iwatsubo), University of Tokyo, Japan; Dept. of Neurology CB 7025 (Dr. Kaufer), University of North Carolina School of Medicine, Chapel Hill; Department of Neurology (Dr. Korczyn), Tel-Aviv University, Israel; Department of Psychiatry (Dr. Kosaka), Fukushimera Hospital, Toyohashi, Japan; Center for Neurodegenerative Disease Research (Drs. Lee and Trojanowski), University of Pennsylvania School of Medicine, Philadelphia; Reta Lila Weston Institute of Neurological Studies (Dr. Lees), Royal Free & UCL Medical School, London, UK; Department of Neurology (Dr. Litvan), Movement Disorder Program, University of Louisville School of Medicine, KY; Department of Clinical Sciences (Dr. Londos), University Hospital, Malmoe, Sweden; Neuropsychology Research Program (Dr. Lopez), University of Pittsburgh Medical College, PA; Department of Radiology (Dr. Minoshima), University of Washington, Seattle; Department of Neurology (Dr. Mizuno), Juntendo University School of Medicine, Tokyo, Japan; Servicio de Neurologia (Dr. Molina), Hospital 12 de Octubre, Madrid, Spain; Clinique Neurologique (Dr. Pasquier), Centre Hospitalier et Universitaire, Lille, France; Department of Neurodegeneration and Restorative Research Center of Neurological Medicine (Dr. Schulz), University of Göttingen, Germany; and Department of Neurology & Neurobiology of Ageing (Dr. Yamada), Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

Notes

Address correspondence and reprint requests to Professor I.G. McKeith, Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, UK; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Empirical Assessment of Transfer Learning Strategies for Dementia Classification Using MRI Images, Journal of Disability Research, 3, 4, (2024).https://doi.org/10.57197/JDR-2024-0047
    Crossref
  2. Molecular Behavior of α-Synuclein Is Associated with Membrane Transport, Lipid Metabolism, and Ubiquitin–Proteasome Pathways in Lewy Body Disease, International Journal of Molecular Sciences, 25, 5, (2676), (2024).https://doi.org/10.3390/ijms25052676
    Crossref
  3. The Cerebrospinal Fluid Free-Glycans Hex1 and HexNAc1Hex1Neu5Ac1 as Potential Biomarkers of Alzheimer’s Disease, Biomolecules, 14, 5, (512), (2024).https://doi.org/10.3390/biom14050512
    Crossref
  4. Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a US perspective of current guidelines and future directions, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1395413
    Crossref
  5. Frontotemporal disorders: the expansive panoply of syndromes and spectrum of etiologies, Frontiers in Neurology, 14, (2024).https://doi.org/10.3389/fneur.2023.1305071
    Crossref
  6. Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same, Journal of Parkinson's Disease, 14, 3, (383-397), (2024).https://doi.org/10.3233/JPD-240002
    Crossref
  7. Self-Reported Late-Life Hypertension Is Associated with a Healthy Cognitive Status and Reduced Alzheimer’s Disease Pathology Burden, Journal of Alzheimer's Disease, 98, 4, (1457-1466), (2024).https://doi.org/10.3233/JAD-231429
    Crossref
  8. Psychosis in Neurodegenerative Dementias: A Systematic Comparative Review, Journal of Alzheimer's Disease, (1-15), (2024).https://doi.org/10.3233/JAD-231363
    Crossref
  9. Under-Diagnosis of Dementia with Lewy Bodies in Individuals Racialized as Black: Hypotheses Regarding Potential Contributors, Journal of Alzheimer's Disease, (1-11), (2024).https://doi.org/10.3233/JAD-231177
    Crossref
  10. Montreal Cognitive Assessment and the Clock Drawing Test to Identify MCI and Predict Dementia in Isolated REM Sleep Behavior Disorder, Neurology, 102, 4, (2024)./doi/10.1212/WNL.0000000000208020
    Abstract
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share